Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Dihydroergotamine nasal spray for the acute treatment of migraine.

Ziegler D, Ford R, Kriegler J, Gallagher RM, Peroutka S, Hammerstad J, Saper J, Hoffert M, Vogel B, Holtz N, et al.

Neurology. 1994 Mar;44(3 Pt 1):447-53.

PMID:
8145914
2.

[Migraine: dihydroergotamine nasal spray--an alternative].

Beubler E.

Wien Med Wochenschr. 1995;145(14):326-31. Review. German.

PMID:
7483646
3.

Symptomatic treatment of migraine in children: a systematic review of medication trials.

Damen L, Bruijn JK, Verhagen AP, Berger MY, Passchier J, Koes BW.

Pediatrics. 2005 Aug;116(2):e295-302. Review.

PMID:
16061583
4.

Dosing and administration of ergotamine tartrate and dihydroergotamine.

Mathew NT.

Headache. 1997;37 Suppl 1:S26-32. Review.

PMID:
9009471
5.

Dihydroergotamine: role in the treatment of migraine.

Sch├╝rks M.

Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1141-8. doi: 10.1517/17425250903164211. Review.

PMID:
19624283
6.

DHE in the pharmacotherapy of migraine: potential for a larger role.

Saper JR, Silberstein S, Dodick D, Rapoport A.

Headache. 2006 Nov;46 Suppl 4:S212-20. Review.

PMID:
17078853
7.

Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.

Lipton RB.

Headache. 1997;37 Suppl 1:S33-41. Review.

PMID:
9009472
8.

Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.

Saper JR, Silberstein S.

Headache. 2006 Nov;46 Suppl 4:S171-81. Review.

PMID:
17078849
9.

The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.

Goadsby PJ.

Cephalalgia. 2008 Sep;28 Suppl 2:36-41. doi: 10.1111/j.1468-2982.2008.01689.x. Review.

PMID:
18715331
10.

Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.

Scott AK.

Clin Neuropharmacol. 1992 Aug;15(4):289-96. Review.

PMID:
1516074
11.

Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.

Silberstein SD, Kori SH.

CNS Drugs. 2013 May;27(5):385-94. doi: 10.1007/s40263-013-0061-2. Review.

PMID:
23620146
12.

Orally inhaled dihydroergotamine: a review.

Tepper SJ.

Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184. Review.

PMID:
24024602
14.

Ergot pharmacology and alternative delivery systems for ergotamine derivatives.

Goldstein J.

Neurology. 1992 Mar;42(3 Suppl 2):45-6. Review.

PMID:
1557192
15.

MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.

Silberstein S.

Expert Opin Pharmacother. 2012 Sep;13(13):1961-8. doi: 10.1517/14656566.2012.711319. Epub 2012 Aug 4. Review.

PMID:
22860628
16.

Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.

Tfelt-Hansen PC.

Cephalalgia. 2013 Oct;33(13):1122-31. doi: 10.1177/0333102413483372. Epub 2013 Apr 15. Review.

PMID:
23588793
17.

Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?

Morren JA, Galvez-Jimenez N.

Expert Opin Pharmacother. 2010 Dec;11(18):3085-93. doi: 10.1517/14656566.2010.533839. Review.

PMID:
21080856
18.
19.

Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.

Tfelt-Hansen PC, Diener HC.

Headache. 2014 Oct;54(9):1523-5. doi: 10.1111/head.12389. Epub 2014 May 26. Review. No abstract available.

PMID:
24862945
20.

Inhaled drug therapy development for the treatment of migraine.

Chua AL, Silberstein S.

Expert Opin Pharmacother. 2016 Sep;17(13):1733-43. doi: 10.1080/14656566.2016.1203901. Epub 2016 Jul 28. Review.

PMID:
27416108

Supplemental Content

Support Center